Abstract 162P
Background
Hepatocellular carcinoma (HCC) after curative treatment has an estimated 5-year recurrence rate up to 70% [1]. Intrahepatic recurrence follows a bimodal pattern, with early recurrence occurring within 2 years and late recurrence occurring at 5 years [2]. It is unknown whether the bimodal recurrence pattern remains in the era of antivirals, which could reduce late recurrence. In this study, we provide an update of the characteristics of recurrence pattern.
Methods
Eligible patients who had received surgery or RFA for HCC from Oct 2000 to Jul 2017 were recruited at the Prince of Wales Hospital, Hong Kong. Patients’ and tumors’ characteristics were collected. Pattern of recurrence was classified by the occurrence of intrahepatic (local) recurrence or presence of distant metastasis (DM). Time-to-recurrence (TTR) and overall survival (OS) measure the time between the diagnosis of HCC to the time of first recurrence and death due to any cause respectively. Both TTR and OS were assessed using Kaplan-Meier Method. Prognostic factors for LR and DM were assessed using univariate and multivariate Cox Proportional Hazards Model.
Results
1082 patients were recruited. There were 908 (84%) males. 834 (77%) patients had HBV and 76 (7%) patients had HCV. 831 (77%) patients had BCLC stage 0/A and 243 (23%) patients had BCLC stage B/C HCC. 997 (92%) and 676 (63%) patients had Child-Pugh A and ALBI grade 1 liver function respectively. Median tumor size was 3.5cm. 834 (77%) patients had solitary HCC, and 99 (9%), 21 (2%) and 126 (12%) patients had 2, 3 and ≥3 HCCs respectively. 863 (80%) patients received surgery and 219 (20%) patients received RFA. The TTR for both LR and DM peaked at 9 to 12 months then dropped progressively. The bimodal recurrence pattern was not apparent. In patients who developed recurrence, median OS was longest in those with LR only at 64.8 months, versus shortest in those who developed DM first then LR at 13.3 months.
Conclusions
In the era of antivirals, the bimodal recurrence pattern is not observed with a marked reduction of late recurrence. The pattern of recurrence influences the prognosis: patients with LR have significantly better OS than DM. These findings are important for future research on adjuvant and salvage treatment for recurrent HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L.L. Chan: Other, Personal, Other, Travel Grant: Roche. K. Mok: Other, Personal, Other, Travel Grant: AstraZeneca, Eisai. S.L. Chan: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, MSD, BMS, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Personal, Research Grant: Eisai, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract